Despite the numerical differences in the SPACE cohort between patients with axSpA and CBP, testing for anti-CD74 IgA antibodies only modestly increased the pre-test probability of axSpA (46.2%) to 58.8% post-test probability. This evidence concerns the gene CD79A and red color blindness.